{"id":"W2247329814","doi":"10.1200/jco.2005.23.16_suppl.3583","title":"An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Irinotecan; Rash; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Discontinuation; Adverse effect; Nausea; Oxaliplatin; Phases of clinical research; Colorectal cancer; Oncology; Cancer; Surgery; Chemotherapy; Breast cancer; Trastuzumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002336786,0.00188185,0.002718894,0.000545541,0.0005467713,0.0009548217,0.001018007,0.001171614,0.003443681],"category_scores_gemma":[0.001136957,0.0007469783,0.001154791,0.0005902039,0.001160782,0.001041146,0.0004729416,0.003081666,0.001028558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009650927,"about_ca_system_score_gemma":0.002038487,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008833997,"about_ca_topic_score_gemma":0.002147839,"domain_scores_codex":[0.9992833,0.0003600558,0.0000371966,0.0001332215,0.00006660941,0.0001197021],"domain_scores_gemma":[0.9988133,0.0001561673,0.0002288455,0.0001028173,0.00007784159,0.0006210493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.759181,0.1357915,0.0085596,0.0005423197,0.0009774033,0.0002942287,0.0002676446,0.001868085,0.03763909,0.0001362142,0.002616193,0.05212673],"study_design_scores_gemma":[0.5099958,0.4752208,0.01014679,0.00001489851,0.0002326767,0.0002085355,0.00004551083,0.001152342,0.002000321,0.00005660167,0.0009023223,0.00002341718],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955037,0.000807344,0.0004993781,0.0001881289,0.00008581981,0.001740674,0.0005909191,0.0000685062,0.0005156241],"genre_scores_gemma":[0.9896208,0.0009942147,0.001964079,0.000655139,0.0002711523,0.003157951,0.001939875,0.00003309135,0.001363803],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003443681,"threshold_uncertainty_score":0.01235825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1988514400215738,"score_gpt":0.5231931102536629,"score_spread":0.3243416702320892,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}